Arrakis Inks First Partnership In RNA-Targeted Collaboration With Roche
Executive Summary
Biotech gets $190m up front in partnership that will discover small molecule RNA-targeted therapies against a range of targets selected by Roche. Arrakis thinks its technology can drug difficult-to-reach targets.
You may also be interested in...
Remix Teams Up With Second Big Pharma With Roche Deal For RNA Technology
The news comes just under two years after Remix signed a partnership with J&J, and the biotech announced the same-day closing of a $60m financing to develop its lead product candidate.
Roche Partnering Finds Upfront Fee Relief In Current Market
Barbara Lueckel, head of research technologies partnering, said Roche’s approach to platform deals has evolved with a focus on “generational technologies” to answer tough scientific questions.
J&J Jumps On RNA-Based Small Molecules Train In Pact With Remix
Deal Snapshot: The deal, with an upfront payment of $45m, is the latest of several involving large biopharma companies and smaller firms focused on small molecule drugs based on RNA biology.